SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-001079
Filing Date
2022-02-10
Accepted
2022-02-10 16:11:16
Documents
14
Period of Report
2022-02-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20220210.htm   iXBRL 8-K 49617
2 EX-99.1 rare-ex99_1.htm EX-99.1 414971
3 GRAPHIC img45776771_0.jpg GRAPHIC 375412
  Complete submission text file 0000950170-22-001079.txt   1116186

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20220210.xsd EX-101.SCH 2501
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20220210_pre.xml EX-101.PRE 9549
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20220210_lab.xml EX-101.LAB 12890
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20220210_htm.xml XML 4518
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 22614017
SIC: 2834 Pharmaceutical Preparations